European Commission approves Merck KEYTRUDA as a HNSCC treatment
Category: #health  By Saipriya Iyer  Date: 2019-11-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

European Commission approves Merck KEYTRUDA as a HNSCC treatment

Merck, a renowned American pharmaceutical firm and one of the largest pharmaceutical companies in the world reportedly announced the approval of KEYTRUDA by European Commission.

Merck anti-PD-1 therapy, has been approved in combination with 5-fluorouracil (5-FU) and platinum chemotherapy or as a monotherapy, for the first-line therapy of patient suffering from unresectable or metastatic recurrent HNSCC (head and neck squamous cell carcinoma) whose tumors express PD-L1 ([CPS] ≥1 combined positive score).

The KEYTRUDA approval enables marketing of the same as monotherapy as well as combination regimen across all 28 EU member states and also in Norway, Iceland and Lichtenstein.

The European Commission approved KEYTRUDA on the basis of outcomes from pivotal KEYNOTE-048 Phase 3 study, in which KEYTRUDA, in comparison to the standard therapy (cetuximab with cisplatin plus 5-FU or carboplatin), showcased a substantial improvement in OS (overall survival) as monotherapy and together with chemotherapy in people whose tumors showed PD-L1 (CPS ≥1).

Professor Kevin Harrington, the KEYNOTE-048 investigator, consultant clinical oncologist of The Royal Marsden NHS Foundation Trust, professor of the biological cancer therapies in The Institute of Cancer Research at London stated that this tumor is particularly debilitating as it could affect a patient’s appearance by being conspicuously visible and impact their day-to-day functions like speaking and eating.

Understanding the heavy demand for new therapies, the company is encouraged by the KEYTRUDA approval in the EU. It would now enable patients to receive treatment with immunotherapy earlier during the course of the treatment.   

Vice President of clinical research at Merck Research Laboratories, Dr. Jonathan Cheng stated that KEYTRUDA has now become the first-in-class anti-PD-1 therapy option within the first setting for unresectable or metastatic recurrent HNSCC. This cancer has been treated in the same manner across the EU for over a decade.

Cheng further added that European Commission approval highlights the company’s commitment to revolutionizing the way this fatal disease is treated across the world.

Source credit: https://www.mrknewsroom.com/news-release/oncology/european-commission-approves-two-new-regimens-mercks-keytruda-pembrolizumab-fi



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...